U.S. Markets closed

Flexion Therapeutics, Inc. (FLXN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
9.40+0.10 (+1.08%)
At close: 4:00PM EDT
9.40 0.00 (0.00%)
After hours: 04:00PM EDT

Flexion Therapeutics, Inc.

10 Mall Road
Suite 301
Burlington, MA 01803
United States
781 305 7777

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees257

Key Executives

NameTitlePayExercisedYear Born
Dr. Michael D. Clayman M.D.Co-Founder, Pres, CEO & Director1.13MN/A1952
Mr. Frederick W. DriscollCFO & Principal Accounting OfficerN/AN/A1951
Scott YoungVP of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Carolyn Beaty ScimemiVP, Legal Affairs & Chief Compliance OfficerN/AN/AN/A
Mr. Mark S. LevineGen. Counsel & Corp. Sec.N/AN/A1973
Dr. Neil BodickConsultantN/AN/A1947
Ms. Christina WillwerthChief Strategy OfficerN/AN/A1971
Ms. Kerry A. WentworthChief Regulatory OfficerN/AN/A1973
Dr. Adam L. Muzikant Ph.D.Chief Bus. OfficerN/AN/A1971
Ms. Melissa LaymanChief Commercial OfficerN/AN/A1969
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.

Corporate Governance

Flexion Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 8; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.